Clinical Trial Update: Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase II study evaluating glofitamab with venetoclax, with or without zanubrutinib, in high-risk mantle cell lymphoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Columvi (glofitamab)
• Venclexa (venetoclax)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Lymphoma, Mantle-Cell | Phase 2 | Status: RECRUITING